JoinTherapeutics S.r.l. was established in 2014 with the aim of exploiting polysaccharides’ features in regenerative medicine.
Strong know-how, clear vision and dynamism allowed the company to achieve important results and paved the way for its business development.
Since its early operation years, the Company has adopted a business model based on a “Virtual Pharma Company” approach which relies on a network of expertise and excellence from the academic and industrial sectors whilst keeping its R&D program and intellectual property development at the heart of the firm.
Our strategy is based on the targeted modification of the biopolymers HA and Chitosan, naturally occurring molecules whose use in the medical field has been well-known for many years.
Our proprietary molecules will neither alter the physical or biological characteristics of the starting polymers, nor their biocompatibility.
Moreover, they have some important attributes, namely their anti-inflammatory activity and the ability to play a key role in tissue regeneration, thereby producing a new range of valuable allies for the medical profession.
Recent scientific research around ß-galactoside-binding proteins (Galectins) has underlined their role in several bio-molecular patterns, such as fine tuning/resolving inflammatory responses, and is the main driver behind Jointherapeutics biopolymers design.
By grafting galactose residues to hyaluronic acid and Chitosan, Jointherapeutics has combined their well-known regenerative properties with anti-inflammatory performance.
The management of inflammatory and tissue regeneration processes by means of specifically designed bio-molecules represents a key element for the successful treatment of several diseases, for instance osteoarthritis, skin aging and respiratory tract conditions.
Osteoarthritis is the most common type of arthritis in the world. It is characterised by pain and inflammation and degeneration of the joint compartment.
The number of OA cases has doubled in the last seventy years.
Recent projections estimate that, within the next 20 years, one in four of all adults will be diagnosed with OA. This would create a figure of 80 million osteoarthritic people in the US alone.
At the moment there is no cure for OA. As a result, current treatments are aimed at addressing symptoms by focusing on physical exercise, FANS, intra-articular injections of hyaluronic acid and corticosteroids injections and use of opioids or surgery.
Skin aging is a complex biological process influenced by a combination of endogenous and exogenous factors.
The goal of skin biorejuvenation is to increase the biosynthetic capacity of the cells, which includes the reconstruction of an optimal physiologic environment, the enhancement of cell activity, hydration and the synthesis of collagen, elastin and hyaluronic acid.
New trends in the development of products for dermo-aesthetics go towards less invasive solutions, i.e. based on the use of natural biopolymers and 3D biomaterial which are able to play both a structural and biological role in the promotion of tissue regeneration during the aging process.
The chronic obstructive pulmonary disease (COPD) is a major public health problem associated with long-term exposure to air pollution.
Recent projections indicate that COPD will become the third leading cause of death in the world. (It was ranked 6thin 1990).
Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial pneumonia, is a chronic, irreversible, and usually lethal lung disease of unknown cause.
In spite of being quite a rare disease, IPF has a very poor prognosis of 3-4 years median survival and 40.000 new cases are diagnosed in Europe every year.
The paper written by researchers of the University of Padua (Italy), was published on line in the February, 28 2020 of Cartilage. The aim of the study was to o compare the effects of the…
The article written by researchers of the University of Padua (Italy) was published in the May 2020 issue of Cells (volume 9(6), pages 1328-1342)…